Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers potent efficacy, while its selectivity provides a safety profile that may set it apart from other highly efficacious—but risk-prone—DMTs. A competitive price offering from Genentech/Roche coupled with a clean, unrestrictive label will ease neurologists’ incorporation of Ocrevus into practice. DRG’s launch tracking series will examine how the perception and performance of Ocrevus evolves through year one in an MS market still waiting for the DMT that balances efficacy and risk better than Tysabri or Tecfidera and in a field that perennially debates the merits of early, aggressive intervention.
What you will learn in this content:
Launch Tracking: Ocrevus Wave 1 (US) Relapsing Forms of Multiple Sclerosis is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.